Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patient Deaths Stop Infinity Pharma’s Phase III HSP90 Trial In Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Sicker patients may have led to result in GI stromal tumors; lung, breast studies with IPI-504 continue.
Advertisement

Related Content

Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Remain Skeptical
Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Analysts Remain Skeptical
Synta’s Ganetespib Could Break The Hsp90i Curse
Synta’s Ganetespib Could Break The Hsp90i Curse
Pharma’s Mega Mergers Reveal Divergent Strategies
Pharma’s Mega Mergers Reveal Divergent Strategies
Infinity Regains Rights To Its Lead Program
Infinity Regains Rights To Its Lead Program
With Innovative Purdue Deal, Infinity Finds Shelter From The Storm

Topics

Advertisement
UsernamePublicRestriction

Register

PS069280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel